DRUG · Mapped RxNorm record
Atrasentan
Normalized identity: atrasentan View linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
A Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy
NCT01399580
Study summary
ClinicalTrials.govA Prospective, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of Atrasentan, Including Thoracic Bioimpedance, in Type 2 Diabetic Subjects With Nephropathy
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Unmapped registry intervention
Placebo
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Advertisement
Conditions
Interventions
AtrasentanDRUG · verified · RxNorm: atrasentan
PlaceboDRUG
Sponsors & collaborators
AbbVie (prior sponsor, Abbott)lead sponsor
Mapped research locations
HoustonTexas, United States2AzusaCalifornia, United States2ChicagoIllinois, United States1Los AngelesCalifornia, United States1DallasTexas, United States1PittsburghPennsylvania, United States1PhoenixArizona, United States1DenverColorado, United States1AlbanyNew York, United States1Baton RougeLouisiana, United States1HollywoodFlorida, United States1AugustaGeorgia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT01399580 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.